

Harvest Medicine Surpasses 15,000 Patient Milestone in under 18 Months of Operation

NAPANEE, Ontario, June 19, 2018 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSXV:ABCN) (“**ABcann**”) is pleased to announce that its wholly-owned subsidiary, Harvest Medicine Inc. (“**Harvest Medicine**” or “**HMed**”), one of Canada’s fastest growing specialty medical cannabis clinics, has surpassed 15,000 active patients, reaching this significant milestone in under 18 months of operation. Harvest Medicine is poised to take its education focused model across Canada, through the opening of new locations and the launch of a purpose-built telemedicine app.

“Our rapid growth is a testament to our patient-centric approach and dedication to providing exceptional care,” stated Shekhar Parmar, Chief Executive Officer of HMed. “We partner with patients to empower them to be more involved in their healthcare and ensure that they receive the safest and most effective medical cannabis treatment for their individualized needs.”

With the opening of a new location in the Edmonton area planned for July, and launch of the telemedicine app expected by the end of the summer, Harvest Medicine is expecting strong continued growth.

“Our vision is to transform the medical cannabis experience for patients and physicians and be recognized as the trusted leader in medical cannabis care across the country,” said Mr. Parmar.

According to Health Canada statistics, the number of registered medical cannabis patients continues to grow dramatically across Canada. At the end of December 2017, there were 269,502 registered medical cannabis patients, a growth of over 54% since April 2017 and over 579% since December 2015.

Demonstrating its commitment to being a leader in the medical market, ABcann acquired Harvest Medicine in January 2018. The insights gained from Harvest Medicine regarding patient experiences, needs, required products and desire for greater guidance inspired ABcann to develop a specialty medical brand: Beacon Medical. Beacon will be a recognized producer of standardized pharma-grade cannabis products that HMed patients will be able to access, together with products of other Licensed Producers.

For more information about Harvest Medicine, visit hmed.ca.

About Harvest Medicine

Harvest Medicine, a wholly-owned subsidiary of ABcann Global Corporation (TSXV:ABCN), is an education focused, patient-centric, cannabis discovery center and clinic that has received tremendous response from its patients. Growing to over 15,000 active patients in under 18 months, HMed is one of Canada’s most successful and fastest growing cannabis clinics. Harvest Medicine is poised to aggressively expand its effective and highly scalable model across the country. Using a highly trained team of medical doctors and Canna Genius educators, Harvest Medicine provides a welcoming environment that focuses on empowering and educating patients on the safe, effective use of medical cannabis. HMed.ca provides

patients clear explanations of the medical cannabis process as well as additional educational resources such as strain reviews, Licensed Producer reviews, success stories, and accessory recommendations.

About ABcann:

ABcann is recognized for high-quality, trusted products and services. It holds production and sales licenses from Health Canada, and its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products. ABcann is expanding its production capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.

For more information about Harvest Medicine, please contact:

Shekhar Parmar at sp@hmed.ca

For more information about ABcann, please contact:

Barry Fishman at barry.fishman@abcannglobal.com or
Michael Bumby at michael.bumby@abcannglobal.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of ABcann and its management regarding the future. Forward looking statements in this news release include statements relating to: the expected timing of opening of the Edmonton HMed clinic; the expected timing of launch of the HMed telemedicine app; HMed's expectation of strong continued growth; HMed's vision to transform the medical cannabis experience for patients and be recognized as a trusted leader in medical cannabis care; and that HMed is poised to aggressively expand its effective and highly scalable model across Canada. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: (i) that there may be delays in the opening of the Edmonton clinic or launch of the telemedicine app; (ii) that the demand for medical cannabis may decrease following the launch of Canada's legal adult use cannabis market, which may slow or reduce HMed's expansion abilities; (iii) changes to applicable governmental regulations that impede HMed's operations; (iv) that HMed's business model may not be scalable as expected or may not be accepted in jurisdictions outside of Alberta; and (v) other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits ABcann or HMed will obtain from them. Readers are urged to consider these factors, and the more extensive risk factors included in ABcann's annual information form dated April 30, 2018, which is available on SEDAR, carefully in evaluating the forward-looking statements contained in this news release, and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. The forward-looking statements in this news release are made as of the date hereof and ABcann disclaims any intent or obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.